Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy

BACKGROUND: Cancer immunotherapy has evolved from interferon-alpha (IFNα) and interleukin-2 in the 1980s to CTLA-4 and PD-1/PD-L1 checkpoint inhibitors (CPIs), the latter highlighting the importance of enhancing T-cell functions. While the search for novel immunomodulatory pathways continues, combin...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Immunother Cancer
Egile Nagusiak: Cubas, Rafael, Khan, Zia, Gong, Qian, Moskalenko, Marina, Xiong, Huizhong, Ou, Qinglin, Pai, Christine, Rodriguez, Ryan, Cheung, Jeanne, Chan, Andrew C
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2020
Gaiak:
Basic Tumor Immunology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604869/
https://ncbi.nlm.nih.gov/pubmed/33127657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001439
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak